Articles related to MEDICAL MEETINGS AND EVENTS

Roswell Park Comprehensive Cancer Center Shines at ASCO 2023 Roswell Park Comprehensive Cancer Center recently showcased a series of groundbreaking research studies at the American Society of Clinical Research (ASCO) 2023 meeting, highlighting their commitment to advancing cancer management and clinical trials. “This study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations.” Dr. Deepak Vadehra from the “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients” study

Reframing Diagnostic Errors towards Diagnostic Excellence: The Five-step Strategy As diagnostic errors continue to pose a significant challenge in the healthcare sector, Dr. Hardeep Singh from the Baylor College of Medicine offers an innovative approach to not just reduce these errors, but to redefine and promote diagnostic excellence. By following a five-step strategy, both physicians and health organizations can enhance diagnostic procedures, ensuring higher accuracy, efficiency, and patient satisfaction. Here are the key highlights from Dr. Singh’s session at the Internal Medicine Meeting 2023:

Pfizer is lagging behind its peers with Ibrance, but the pharma giant is attempting to unveil the potential of CDK2 inhibitors to overcome CDK4/6 resistance. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer and Blueprint gave presentations on posters about their respective agents, and Incyte, Cyclacel, and a few private biotechs also had clinical trials going on. Although there are some positive signs, the research is still in its very early stages, and it is not apparent whether CDK2 inhibition is a workable monotherapy method.

Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting:

Unraveling the ALS Treatment Landscape: An Insightful Webinar Pharmacists, step into an enlightening discussion about the ALS treatment landscape on June 14th from 2:00 – 3:00 PM EST. Unearth key insights from AMCP’s Market Insights Roundtable and explore strategies to navigate patient access barriers, ultimately enriching ALS patients’ quality of life. Firstly, the webinar presents a golden opportunity for pharmacists to deepen their understanding of Amyotrophic Lateral Sclerosis (ALS), a rapidly progressing neurodegenerative disease. Our distinguished speakers will guide you through the current and evolving ALS treatment landscape, emphasizing the differences between clinical trial environments and real-life experiences. Further along, you’ll gain invaluable insights into the patient journey and the burden associated with ALS. In highlighting the current access barriers that patients face, the webinar focuses on a health plan’s concerted effort to mitigate these hurdles, providing valuable lessons for all healthcare stakeholders. Lastly, the importance of collaboration in the decision-making process to minimize access to care barriers will be underscored. With panelists like Ryan Haumschild, Director of Pharmacy at Emory Healthcare and Winship Cancer Institute, and Ryan Bitton, Senior Director of Pharmacy Services at Health Plan of Nevada, this is a conversation you won’t want to miss. Join us […]

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types. Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential. Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough. Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented. Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid […]